Related Experiment Video
Updated: Aug 15, 2026
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
[Treatment of lymphogranulomatosis in children]
Insights
This study on pediatric lymphogranulomatosis treatment found that personalized care, including immunocorrection with taktivin, significantly improved survival rates. Over 93% of children survived beyond five years with tailored treatment programs.
Area of Science:
- Pediatric Oncology
- Immunology
Context:
- Analysis of 366 children treated for lymphogranulomatosis between 1976 and 1990.
- Utilized three distinct combined treatment programs.
Purpose:
- To evaluate the effectiveness of individualized treatment strategies for pediatric lymphogranulomatosis.
- To assess the role of immunocorrection in managing immunity disorders within this patient group.
Summary:
- Demonstrated the necessity of personalized treatment approaches based on specific patient predictors.
- Taktivin was administered for immunocorrection in children with immune system disorders.
- Optimized treatment protocols led to a significant increase in long-term survival.
Impact:
- Achieved a 5-year survival rate exceeding 93.8% in the treated pediatric cohort.
- Highlights the importance of tailored therapeutic interventions in improving outcomes for lymphogranulomatosis.
- Provides evidence for the efficacy of combined treatment modalities and immunomodulation.
Abstract:
The authors analyze the results of the treatment of 366 children afflicted with lymphogranulomatosis. All the patients received treatment from 1976 to 1990 according to three combined programs. The necessity is demonstrated of the individual treatment with regard to the predictors. Immunocorrection by means of taktivin was employed in patients with immunity disorders. The perfection of a complex of treatment measures favoured an increase of the survival to over 5 years in 93.8% of cases.
